LifeVantage Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2020. The filing also reports fourth-quarter results; despite the request metadata referencing “2019 Q4,” this is the FY2020 annual report. Amounts below are in U.S. dollars.
Business context
LifeVantage sells dietary supplements, skin and hair care, and other wellness products primarily through independent distributors and a direct-selling model. The United States generated about 67% of FY2020 revenue and Japan about 18%. Protandim and TrueScience together accounted for 77.3% of revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $232.9 million | $226.0 million |
| Gross profit / margin | $195.0 million / 83.7% | $188.0 million / 83.2% |
| Operating income / margin | $15.5 million / 6.6% | $9.8 million / 4.3% |
| Net income / diluted EPS | $11.5 million / $0.79 | $7.4 million / $0.50 |
| Cash from operating activities | $18.3 million | $17.8 million |
| Cash and cash equivalents at year-end | $22.1 million | $18.8 million |
| Working capital at year-end | $18.8 million | $17.0 million |
| Long-term debt at year-end | None | None shown; $1.5 million current debt |
FY2020 net revenue increased 3.1% year over year. Gross margin improved, while operating income rose 57.6% and net income rose 55.5%. The company repaid the remaining term loan during the year; its $5 million revolving facility had no outstanding balance at June 30, 2020. Management said cash and expected operating cash flow should cover requirements for at least 12 months. No cash dividends have been paid or are anticipated.
For the fourth quarter of FY2020, revenue was $59.4 million and net income was $3.8 million, compared with $56.2 million and $3.9 million, respectively, in the fourth quarter of FY2019.
Material changes and management commentary
- Protandim revenue increased to $156.3 million from $144.1 million; TrueScience revenue declined to $23.7 million from $24.9 million.
- Active distributors increased 10.6% to about 73,000, while active customers decreased 10.9% to about 106,000; total active accounts fell 3.2% to about 179,000.
- Australia and New Zealand revenue grew 54.9%, supported by New Zealand’s November 2019 launch. Greater China revenue fell 15.7%; management cited Hong Kong weakness, the pandemic and regional geopolitical events.
- The company launched Protandim NAD Synergizer, enhanced distributor compensation programs, and expanded virtual training and digital tools. Singapore and Malaysia market launches were delayed by COVID-19.
- Management reported adapting to remote work and virtual events and experiencing minimal supply-chain impact to date, while noting that the pandemic’s duration and future business effects remained uncertain.
Outlook, risks and unusual items
- No numerical revenue or earnings guidance is provided. Management expects liquidity to be sufficient for at least the next 12 months, subject to operating performance and pandemic developments.
- Key risks include COVID-19 disruption, reliance on distributors and a concentrated product portfolio, product-claim and direct-selling regulation, competition, foreign exchange exposure, third-party manufacturing and supply-chain dependence, and inventory management.
- A 10% strengthening of the U.S. dollar against relevant foreign currencies would have reduced FY2020 revenue by an estimated $7.0 million, or 3.0%.
- A securities class action remained pending; the company had not accrued a loss, stating that loss was not probable or estimable, and intends to defend the case. The filing says no other probable loss contingencies required accrual or disclosure.
- The company recorded a $480,000 uncertain tax liability related to potential Taiwan withholding tax on intercompany charges; it expected to determine during FY2021 whether payment was required.
- The company converted a $2.0 million convertible note, with $2.2 million aggregate consideration, into GEG shares. It reported a $2.2 million equity-securities investment with no impairment recognized at year-end. Two directors serve on GEG’s board, and LifeVantage paid GEG $1.2 million for software development during FY2020.
- FY2020 financing cash outflow included $5.4 million of stock repurchases and $6.2 million of shares withheld for employee tax obligations. The repurchase authorization had $3.4 million remaining at year-end and was scheduled to expire November 27, 2020.
Important facts for investors to verify
- Whether active customer declines persist and distributor growth converts into sustained sales and retention.
- How COVID-19 affects demand, distributor recruitment, supply availability, and delayed international expansion.
- Performance of the concentrated Protandim and TrueScience product lines and the uptake of newer products.
- Developments in the pending class action and the Taiwan withholding-tax assessment.
- Valuation and financial condition of GEG, given the $2.2 million investment and related-party service relationship.
- Liquidity, covenant and capital-allocation implications of the revolving credit facility, lease commitments, and stock repurchase authorization.